Stimulation of renin release by 6-oxo-prostaglandin E1 and prostacyclin.
1 Renin release induced by 6-oxo-prostaglandin E1 (6-oxo-PGE1) was compared to release in response to prostacyclin (PGI2) and 6-oxo-PGF1 alpha in slices of rabbit renal cortex. 2 Krebs-Ringer medium bathing slices of renal cortex was collected for renin assay after four successive 20 min intervals (periods I-IV). Renin release did not increase during periods I to IV in untreated slices. Agonists were added, only once, at the beginning of period III. Between periods III and IV, the incubation solution was aspirated and replaced with fresh medium. 3 PGI2 increased renin release during period III while 6-oxo-PGE1 stimulated release during periods III and IV. 6-oxo-PGE1 stimulated renin release (24%-74%) in concentrations ranging from 1-33 microM while PGI2 stimulated release at 10 microM (60%) but not at 5 microM. 6-oxo-PGF1 alpha, 10 microM, did not release renin during period III (period III, 9%), but caused a small rise in period IV (29%). 4 6-oxo-PGE1, unlike PGI2, was stable under the incubation conditions (pH 7.4, 37 degrees C) as indicated by recovery of undiminished platelet anti-aggregatory material after 20 min. 5 In the rabbit kidney, activity of 9-hydroxyprostaglandin dehydrogenase was greatest in the cortex and negligible in the papilla, corresponding to the zonal distribution of renin. 6 The prominent and sustained in vitro renin releasing effect of 6-oxo-PGE1, as well as the cortical localization of enzyme activity capable of generating this stable prostacyclin metabolite, suggest that formation of 6-oxo-PGE1 may contribute to PGI2-induced renin release and may explain the delayed stimulation caused by 6-oxo-PGF1 alpha.
D015121:6-Ketoprostaglandin F1 alpha / Q000494:pharmacology; D000527:Alprostadil / Q000031:analogs & derivatives*; D000818:Animals; D011464:Epoprostenol / Q000494:pharmacology*; D006911:Hydroxyprostaglandin Dehydrogenases / Q000378:metabolism; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology; D007672:Kidney Cortex / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D011453:Prostaglandins / Q000494:pharmacology*; D011458:Prostaglandins E / Q000494:pharmacology; D011465:Prostaglandins, Synthetic / Q000494:pharmacology*; D011817:Rabbits; D012083:Renin / Q000378:metabolism*
D011453:Prostaglandins; D011458:Prostaglandins E; D011465:Prostaglandins, Synthetic; D015121:6-Ketoprostaglandin F1 alpha; C022950:6-ketoprostaglandin E1; D011464:Epoprostenol; D006911:Hydroxyprostaglandin Dehydrogenases; D012083:Renin; D000527:Alprostadil; D007545:Isoproterenol